RecruitingNot Applicable

Genomic Investigation of Unusual Responders

Canada100 participantsStarted 2013-11-01

Plain-language summary

Studies have shown that tumors from the same patient may respond very differently to the same therapeutic agents. This study aims to investigate the genetic basis of tumors that respond abnormally well or poorly to therapeutic agents in an effort to understand the fundamental genetic basis of this response. The present protocol seeks to retrospectively perform Exome, next-generation (DNA) sequencing and/or other molecular techniques on tumor samples to identify the genetic basis of a patient's exceptional response to chemotherapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. The patient must have either an exceptionally good or poor response to treatment, as indicated by their treating physician.
✓. The exact definition of this is adaptable to the disease but a suggested guideline is a Complete Response, Partial Response or progression free interval of at least 6 months
✓. Exceptionally poor response includes patients who were expected to respond favourably to a treatment but instead responded poorly (e.g dramatic tumor growth or death)
✓. The patient must have sufficient archival tumor available for sequencing.
✓. Deceased patients will also be considered for analysis (up to 30 patients per year) if they meet at least one of the following requirements:

What they're measuring

Genomic Characterization of Tumor Samples

Timeframe: Through study completion, up to 2 years

Trial details

NCT IDNCT03740503

SponsorUniversity Health Network, Toronto

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-11

Contact for this trial

Celeste Yu

416-946-4501 celeste.yu@uhn.ca

View on ClinicalTrials.gov More Cancer trials